Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 538
- Registration Number
- NCT00721123
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: TocilizumabDrug: Disease-modifying anti-rheumatic drugsDrug: Non-steroidal anti-inflammatory drugsDrug: Oral corticosteroids
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2067
- Registration Number
- NCT00720798
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 201
- Registration Number
- NCT00718315
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 421
- Registration Number
- NCT00717821
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
Phase 3
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 128
- Registration Number
- NCT00718549
- Locations
- 🇧🇾
City Clinical Hospital #9, Minsk, Belarus
🇵🇱Szpital Uniwersytecki W Krakowie; Klinika Hematologii, Krakow, Poland
🇵🇱Medical University, Independent Public Clinical Hospital; Dept. of Hematology, SPSK, Bialystok, Poland
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00717405
Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00717366
- Locations
- 🇪🇸
Hospital Universitario La Paz: Nefrologia Pediatrica, Madrid, Spain
🇮🇹IRCCS G. Gaslini; U.O. Nefrologia, Dialisi e Trapianto, Genova, Liguria, Italy
🇪🇸Hospital Universitario la Fe; Servicio de Nefrologia Pediatrica, Valencia, Spain
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1189
- Registration Number
- NCT00717457
A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.
Phase 4
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT00717314
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
Phase 1
Completed
- Conditions
- Pancreatic Neoplasm
- Interventions
- Biological: monoclonal antibodyDrug: chemotherapy
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT00711191
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath